Cipla reported INR250.61B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Arca Biopharma USD 941.49M 56.93M Sep/2026
aTyr Pharma USD 50.16M 8.21M Sep/2026
Bio Path USD 677K 14K Mar/2026
Brainstorm Cell Therapeutics USD 316K 132K Jun/2026
Capricor Therapeutics USD 202.25M 39.88M Sep/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Cipla INR 250.61B 9.14B Sep/2026
Dr.Reddys Laboratories INR 297.32B 2.01B Sep/2026
Immunic USD 135.09M 22.75M Sep/2026
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sun Pharmaceuticals INR 692.67B 54.06B Sep/2026
TherapeuticsMD USD 11.82M 303K Jun/2024
UPL INR 475.77B 52.82B Sep/2026